Short-term esomeprazole treatment resolves reflux symptoms in patients with nonerosive symptomatic gastro-oesophageal reflux disease (gord) and frequent heartburn
- At: 2014 FIP Congress in Bangkok (Thailand)
- Type: Poster
- By: KATZ, Philip (Einstein Medical Center, Division of Gastroenterology, Philadelphia, United States of America)
- Co-author(s): Le Moigne, Anne (Pfizer Consumer Healthcare, Madison, United States of America)
Park, Kelly (Pfizer Consumer Healthcare, Madison, United States of America)
Pollack, Charles (Pfizer Consumer Healthcare, Madison, United States of America)
Background: Pharmacists are often asked about short-term treatments of reflux symptoms such as heartburn (HB) and acid regurgitation. We evaluated 14-day efficacy from 2 similarly designed randomized controlled studies of esomeprazole (ESO) 20 mg and 40 mg in patients likely to seek self-treatment in a pharmacy setting.
Setting: Study 1 (N=368).. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.